Severe acute respiratory syndrome-related coronavirus

DGAP-News: Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

Retrieved on: 
Tuesday, June 30, 2020
Viruses, Infectious diseases, Microbiology, RNA, RNA virus, Viral disease, Influenza, Human orthopneumovirus, Severe acute respiratory syndrome-related coronavirus, Negative-sense single-stranded RNA virus, Defective interfering particle, ATR-002's mode of action with dual benefit, Atriva Therapeutics GmbH

[1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.

Key Points: 
  • [1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.
  • As the virus is unable to perform this function by itself, this represents an Achilles heel of virus replication.
  • [3]
    "By targeting the enzyme MEK, an essential component of the signalling cascade, ATR-002 inhibits this pathway and, thus, leads to a blockade of viral replication.
  • This pathway is central for replication of many RNA viruses, such as the influenza virus, hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19.

Zep Announces Expanded Production Capacity at Operations Facilities Amid High Demand for Disinfecting Products During COVID-19

Retrieved on: 
Tuesday, June 30, 2020
Other Manufacturing, Health, Specialty, Infectious diseases, Chemicals, Plastics, Food, Beverage, Manufacturing, Retail, Viruses, Articles, Health, Zoonoses, Coronaviridae, Animal virology, Health in Saudi Arabia, In Saudi Arabia, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome

We anticipate expanded operations will create at least 70 new jobs across the organization.

Key Points: 
  • We anticipate expanded operations will create at least 70 new jobs across the organization.
  • Zep has seen an exponential lift in demand for the companys EPA-registered disinfectant and hand sanitizing products since the start of the global pandemic.
  • Zep offers a wide array of solutions qualified for use against SARS-CoV-2, the novel coronavirus that causes COVID-19.
  • To learn more about Zep products visit Zep.com or speak with one of our local solutions experts or distributor partners.

Coronavirus (COVID-19) Update: Daily Roundup

Retrieved on: 
Monday, June 29, 2020
Health, Emergency Use Authorization, Food and Drug Administration, Severe acute respiratory syndrome-related coronavirus

The FDA's action is in support of its efforts to protect the public health.

Key Points: 
  • The FDA's action is in support of its efforts to protect the public health.
  • FTC's action enforces provisions of the FTC Act, 15 U.S.C.
  • Failure to immediately correct the unapproved new drug and misbranding violations could result in legal action, including, without limitation, seizure and injunction.
  • FDA issued Emergency Use Authorizations (EUAs) for the following SARS-CoV-2 molecular diagnostic tests:

Beckman Coulter's SARS-CoV-2 IgG Antibody Test Receives FDA Emergency Use Authorization

Retrieved on: 
Monday, June 29, 2020
Coulter, Emergency Use Authorization, Beckman, Severe acute respiratory syndrome-related coronavirus, Companies

BREA, Calif., June29, 2020 /PRNewswire/ -- Beckman Coulter today announced that its Access SARS-CoV-2 IgG assay has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA).

Key Points: 
  • BREA, Calif., June29, 2020 /PRNewswire/ -- Beckman Coulter today announced that its Access SARS-CoV-2 IgG assay has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA).
  • Beckman Coulter has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the U.S., and has begun distribution of the new antibody test globally to countries that accept the FDA EUA and CE Mark.
  • Henry Ford Health System was one of the first health systems to receive Beckman Coulter's test and independently validate its performance.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Cell Publication Elucidates How SARS-CoV-2 Dramatically Rewires Important Cell Programming; Identifies Existing Therapeutics That May Fight COVID-19

Retrieved on: 
Sunday, June 28, 2020
Viruses, Severe acute respiratory syndrome-related coronavirus, Kinase, Vaccinia

The scientists collaborated with Zoic Labs to overlay this new phosphorylation information onto the interactive version of the previously published protein-protein interaction map .

Key Points: 
  • The scientists collaborated with Zoic Labs to overlay this new phosphorylation information onto the interactive version of the previously published protein-protein interaction map .
  • The team determined that 40 of the 332 human proteins that interact with SARS-CoV-2 were significantly differentially phosphorylated in cells infected with SARS-CoV-2.
  • Because kinases possess certain structural features, they are very druggable targets with more than 500 compounds commercially available or in development.
  • Conversely, other viruses including vaccinia, Ebola and Marburg take over the host cell cytoskeleton to promote egress and rapid cell-to-cell spread.

Moore Kuehn, PLLC Encourages Investors of CSPR , ENPH, or CEMI to Contact Law Firm

Retrieved on: 
Thursday, June 25, 2020
Glycoproteins, Branches of biology, Antibodies, Biology, Immunology, Severe acute respiratory syndrome-related coronavirus, Immunoglobulin G, Immunoglobulin M

The Company misled investors regarding its FDA authorization for the Chembio Diagnostic System DPP COVID-19 IgM/IgG System, a SARS-CoV-2 antibody test (the "DPP Test").

Key Points: 
  • The Company misled investors regarding its FDA authorization for the Chembio Diagnostic System DPP COVID-19 IgM/IgG System, a SARS-CoV-2 antibody test (the "DPP Test").
  • On this news, Chembio's stock fell over 60% in intraday trading on June 17, 2020.
  • If you own CSPR , ENPH , or CEMI please contact Fletcher Moore, Esq.
  • Moore Kuehn is a New York-based law firm with attorneys representing investors and consumers.

Entos Pharmaceuticals Announces Selection of Lead DNA Vaccine Candidates for COVID-19 and a $4.2M Award to Move Forward with Phase I/II Human Trials

Retrieved on: 
Thursday, June 25, 2020
Health, Infectious diseases, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Immunology, Vaccination, Branches of biology, Virology, Immunogenicity, Vaccines, DNA vaccination, Vaccine, Antibody, Severe acute respiratory syndrome-related coronavirus

In collaboration with academic and industrial partners, Entos rapidly developed a panel of recombinant plasmid DNA vaccine candidates encoding in silico-optimized and conserved regions of the SARS-CoV-2 spike protein.

Key Points: 
  • In collaboration with academic and industrial partners, Entos rapidly developed a panel of recombinant plasmid DNA vaccine candidates encoding in silico-optimized and conserved regions of the SARS-CoV-2 spike protein.
  • The two lead Covigenix candidates showed robust preclinical in vivo results, achieving all vaccine profile targets, including potency, ADE safety assessment, high immunogenicity, and efficacy.
  • Lead Covigenix candidates stimulated neutralizing antibody levels and balanced T helper cell immunity in mouse models.
  • We look forward to continue working closely with our collaborators to initiate Phase I/II human clinical trials this summer.

Virality Diagnostics Antibody Test Wins FDA EUA

Retrieved on: 
Thursday, June 25, 2020
Medical specialties, Medicine, Immunologic tests, Branches of biology, Immunology, Antibody, Glycoproteins, Severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome-related coronavirus, ELISA, Emergency Use Authorization, Immunoassay

NEW HAVEN, Conn., June 25, 2020 /PRNewswire/ -- The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for a rapid COVID-19 antibody test distributed by Virality Diagnostics LLC,manufactured by Biohit (Hefei).This test, authorized on June 18th, 2020, is a rapid SARS-CoV-2 lateral flow immunoassay (LFA) which detects both IgG and IgM antibodies with 98.5% accuracy.

Key Points: 
  • NEW HAVEN, Conn., June 25, 2020 /PRNewswire/ -- The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for a rapid COVID-19 antibody test distributed by Virality Diagnostics LLC,manufactured by Biohit (Hefei).This test, authorized on June 18th, 2020, is a rapid SARS-CoV-2 lateral flow immunoassay (LFA) which detects both IgG and IgM antibodies with 98.5% accuracy.
  • The antibody test measures the body's immune response to determine whether an individual has produced certain antibodies in response to a SARS-CoV-2infection, indicating past exposure to and infection by the novel coronavirus.
  • Virality has the potential to supplymore thana million antibody test kits every day.With continuous validation of various antibody tests, and the development of novel antigen tests, Virality aims to help keep its customers healthy and get the world back to work.
  • Virality is committed to providing the highest quality products to its customers around the world, and we are delighted to be offering this highly reliable antibody test."

Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, June 25, 2020
Vaccination, Vaccine, Virology, Severe acute respiratory syndrome-related coronavirus, Provisional application, Patent and Trademark Office

Dr. Eva-Kathrin Ehmoser, Professor and Head of the Institute for Synthetic Bioarchitectures at BOKU, serves as the co-principal investigator of the COVID-19 vaccine program.

Key Points: 
  • Dr. Eva-Kathrin Ehmoser, Professor and Head of the Institute for Synthetic Bioarchitectures at BOKU, serves as the co-principal investigator of the COVID-19 vaccine program.
  • This vaccine strategy has the dual advantages of ease of manufacturing and delivery.
  • Avalon and Professor Sleytr have jointly filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) pertaining to the nanoparticle S-layer based vaccine against SARS-CoV-2.
  • We are working swiftly and diligently with BOKU to complete the laboratory testing and characterization of the S-layer fusion protein SARS-CoV-2 vaccine candidate.

Babson Diagnostics Receives FDA Emergency Use Authorization for its SARS-CoV-2 IgG Antibody Test

Retrieved on: 
Thursday, June 25, 2020
Health, FDA, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Branches of biology, Medical specialties, Glycoproteins, Medicine, Immunology, Antibody, Emergency Use Authorization, Severe acute respiratory syndrome-related coronavirus, Immunoglobulin G, ELISA

Babson Diagnostics (Babson), a transformative diagnostic blood testing company, announced today that its SARS-CoV-2 IgG antibody test, Babson Diagnostics aC19G1, has received emergency use authorization (EUA) from the Food and Drug Administration (FDA).

Key Points: 
  • Babson Diagnostics (Babson), a transformative diagnostic blood testing company, announced today that its SARS-CoV-2 IgG antibody test, Babson Diagnostics aC19G1, has received emergency use authorization (EUA) from the Food and Drug Administration (FDA).
  • Babson Diagnostics aC19G1 is a COVID-19 serology test that enables the qualitative detection of IgG antibodies to SARS-CoV-2 with 100% sensitivity and 100% specificity.
  • View the full release here: https://www.businesswire.com/news/home/20200625005190/en/
    Babson Diagnostics aC19G1 COVID-19 serology test, the companys first-generation test designed to aid in identifying individuals with an adaptive immune response to SARS-CoV-2.
  • Babson launched its IgG antibody test on April 30, 2020.